Payment overview · 2025
General Payments
$1,076.73
52 reported records · 7 companies
Healthcare provider profile · identity verified
Eddys Disla, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · NEW YORK, NY · NPI 1679619233
Verified facts
What the public records show
CMS Open Payments records show Eddys Disla, M.D. received $1,076.73 in general payments during 2025 across 52 reported records.
Novartis Pharmaceuticals Corporation accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Benlysta, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HUMIRA as an associated drug or biological on 1828 records involving 689 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Humira by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Enbrel by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Benlysta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $262.17 | 24.4% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $227.39 | 21.1% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $189.48 | 17.6% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $129.75 | 12.1% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $128.91 | 12.0% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $96.57 | 9.0% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.46 | 3.9% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,076.73 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $262.17 | 11 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $227.39 | 15 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $130.40 | 5 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $112.39 | 6 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $77.19 | 3 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $68.99 | 3 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $60.76 | 3 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $59.08 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $42.46 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | HUMIRA open payments reported associated product |
CMS Open Payments — General Payments 1828 supporting records · 689 recipient NPIs · example record 1201353784 |
Humira · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
117 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
122 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 1226 | 238 |
| Sulfasalazine | Sulfasalazine | 1169 | 222 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 1041 | 166 |
| Montelukast Sodium | Montelukast Sodium | 905 | 155 |
| Methotrexate | Methotrexate Sodium | 892 | 144 |
| Gabapentin | Gabapentin | 846 | 198 |
| Folic Acid | Folic Acid | 500 | 92 |
| Alendronate Sodium | Alendronate Sodium | 486 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 475 | 122 |
| Omeprazole | Omeprazole | 459 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 440 | 112 |
| Ammonium Lactate | Ammonium Lactate | 432 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 405 | 87 |
| Carvedilol | Carvedilol | 401 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 366 | 111 |
| Losartan Potassium | Losartan Potassium | 346 | 89 |
| Prednisone | Prednisone | 324 | 91 |
| Metformin Hcl | Metformin Hcl | 305 | 84 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 304 | 58 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 257 | 65 |
| Fluticasone Propionate | Fluticasone Propionate | 254 | 53 |
| Sertraline Hcl | Sertraline Hcl | 252 | 43 |
| Vascepa | Icosapent Ethyl | 252 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 241 | 60 |
| Famotidine | Famotidine | 235 | 52 |
| Enbrel Sureclick | Etanercept | 223 | 32 |
| Lactulose | Lactulose | 220 | 57 |
| Diclofenac Sodium | Diclofenac Sodium | 212 | 56 |
| Meclizine Hcl | Meclizine Hcl | 202 | 38 |
| Colchicine | Colchicine | 194 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 188 | 38 |
| Memantine Hcl | Memantine Hcl | 184 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 177 | 49 |
| Doxycycline Hyclate | Doxycycline Hyclate | 173 | 67 |
| Ketoconazole | Ketoconazole | 172 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 47 |
| Furosemide | Furosemide | 153 | 27 |
| Hydrocortisone | Hydrocortisone | 153 | 32 |
| Rasuvo | Methotrexate/Pf | 135 | 17 |
| Ursodiol | Ursodiol | 133 | 24 |
| Spironolactone | Spironolactone | 130 | 22 |
| Mirtazapine | Mirtazapine | 129 | 17 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 123 | 29 |
| Farxiga | Dapagliflozin Propanediol | 122 | 23 |
| Allopurinol | Allopurinol | 121 | 20 |
| Simvastatin | Simvastatin | 118 | 29 |
| Linzess | Linaclotide | 117 | 19 |
| Meloxicam | Meloxicam | 116 | 25 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 113 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 112 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 106 | 34 |
| Nifedipine Er | Nifedipine | 103 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 99 | 30 |
| Lisinopril | Lisinopril | 99 | 33 |
| Eliquis | Apixaban | 88 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 19 |
| Nystatin | Nystatin | 82 | 17 |
| Trazodone Hcl | Trazodone Hcl | 79 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 15 |
| Taltz Autoinjector | Ixekizumab | 75 | 18 |
| Glimepiride | Glimepiride | 74 | 19 |
| Metformin Hcl Er | Metformin Hcl | 74 | 17 |
| Valacyclovir | Valacyclovir Hcl | 74 | 24 |
| Sulfasalazine Dr | Sulfasalazine | 73 | 15 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 70 | 13 |
| Xarelto | Rivaroxaban | 69 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 67 | 11 |
| Mometasone Furoate | Mometasone Furoate | 67 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 13 |
| Calcitriol | Calcitriol | 63 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 16 |
| Icosapent Ethyl | Icosapent Ethyl | 60 | 15 |
| Ozempic | Semaglutide | 60 | 17 |
| Nystop | Nystatin | 57 | suppressed |
| Finasteride | Finasteride | 55 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | suppressed |
| Humira(Cf) Pen | Adalimumab | 53 | suppressed |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Jardiance | Empagliflozin | 48 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 47 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 47 | 15 |
| Fluocinonide | Fluocinonide | 46 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 46 | suppressed |
| Atenolol | Atenolol | 43 | 15 |
| Azelastine Hcl | Azelastine Hcl | 43 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 43 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 41 | 11 |
| Clotrimazole | Clotrimazole | 41 | 11 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 41 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 40 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Constulose | Lactulose | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Chlorthalidone | Chlorthalidone | 38 | 11 |
| Humira Pen | Adalimumab | 38 | suppressed |
| Enbrel | Etanercept | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 36 | 11 |
| Humira | Adalimumab | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Nitroglycerin | Nitroglycerin | 35 | 11 |
| Acarbose | Acarbose | 34 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 34 | suppressed |
| Metronidazole | Metronidazole | 33 | 14 |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 31 | suppressed |
| Proctozone-Hc | Hydrocortisone | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 22 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 28 | 14 |
| Timolol Maleate | Timolol Maleate | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | suppressed |
| Procto-Med Hc | Hydrocortisone | 26 | suppressed |
| Orencia Clickject | Abatacept | 25 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Simponi | Golimumab | 25 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 25 | suppressed |
| Benlysta | Belimumab | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Otrexup | Methotrexate/Pf | 24 | suppressed |
| Repaglinide | Repaglinide | 24 | 11 |
| Valsartan | Valsartan | 24 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Prednisolone | Prednisolone | 23 | 19 |
| Sucralfate | Sucralfate | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Kevzara | Sarilumab | 22 | suppressed |
| Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 22 | 20 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | 11 |
| Azathioprine | Azathioprine | 20 | suppressed |
| Enulose | Lactulose | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Restasis | Cyclosporine | 19 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Cosentyx (2 Syringes) | Secukinumab | 17 | suppressed |
| Leflunomide | Leflunomide | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Actemra | Tocilizumab | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Cosentyx Syringe | Secukinumab | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Terconazole | Terconazole | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Cimzia (2 Pack) | Certolizumab Pegol | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Mitigare | Colchicine | 12 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Tetracycline Hcl | Tetracycline Hcl | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Bystolic | Nebivolol Hcl | 11 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,076.73 · 52 records | Novartis Pharmaceuticals Corporation | BENLYSTA, BREZTRI, COSENTYX, KRYSTEXXA, RINVOQ, SKYRIZI, TALTZ, TAVNEOS, TRELEGY ELLIPTA, XELJANZ | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Benlysta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error